Try Alerts Free   |   Login
Health Care › Services-Hospitals

MD Price Correlated With Financials For MEDNAX

Free historical financial statements for MEDNAX Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 47 quarters since 2011. Compare with MD stock chart to see long term trends.

MD Stock Compared to Quarterly

MD Income Statement

Revenue, Net:489915000
Revenue Per Share:5.8976
Selling, General & Admin Expense:57888000
Total Operating Expenses:442528000
Operating Income:47387000
Income Taxes:10051000
Net Income:30728000
Earnings Per Share, Basic:0.37
Shares Outstanding, Basic Avg:83069757

MD Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:8956000
Change in Accounts Receiveable:-15449000
Net Cash from Operations:95094000
Net Cash from Operations Per Share:1.1447
Repurchases/Buybacks Common Stock:21477000
Net Cash from Financing Activities:-82662000
Purchases of Businesses, Net of Cash:0
Net Cash from Investing Activities:-6088000
Net Change in Cash & Equivalents:-5420000

MD Balance Sheet

Cash and Cash Equivalents:8668000
Accounts Receivable, Net:294351000
Total Current Assets:423707000
Property, Plant & Equipment, Net:71656000
Total Assets:2331957000
Accounts Payable:27136000
Total Short-Term Liabilities:351694000
Total Liabilities:1473290000

Major Holders (from 13F filings)

Investment Type
Value (x$1000)
increase or decrease
Blackrock Inc.
13,565,624 sh
-406,434 sh
Vanguard Group Inc
9,666,294 sh
-633,464 sh
Earnest Partners LLC
6,760,729 sh
302,300 sh
Alliancebernstein L.P.
6,496,913 sh
-751,318 sh
Lazard Asset Management LLC
6,019,923 sh
1,678,258 sh
Starboard Value LP
5,915,000 sh
Arrowmark Colorado Holdings LLC
3,641,718 sh
890,765 sh
Dimensional Fund Advisors LP
3,400,978 sh
-199,760 sh
State Street Corp
3,373,969 sh
72,731 sh
River Road Asset Management, LLC
2,900,916 sh
-91,047 sh
New York State Common Retirement Fund
1,525,869 sh
-39,438 sh
Geode Capital Management, LLC
1,469,666 sh
-11,349 sh
Charles Schwab Investment Management Inc
1,288,687 sh
58,081 sh
D. E. Shaw & Co., Inc.
1,007,348 sh
90,053 sh
Northern Trust Corp
985,655 sh
-111,234 sh
Bank Of New York Mellon Corp
852,091 sh
-29,071 sh
Segall Bryant & Hamill, LLC
820,492 sh
15,645 sh
Morgan Stanley
807,169 sh
-48,308 sh
Aristotle Capital Boston, LLC
773,954 sh
-66,585 sh
Palisade Capital Management LLC/Nj
769,891 sh
150,357 sh
1. Basis of Presentation and New Accounting Pronouncements: The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Mednax, Inc. and its consolidated subsidiaries (collectively, “MDX”) together with the accounts of MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the “affiliated professional contractors”). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms “Mednax” and the “Company” refer collectively to Mednax Inc., its subsidiaries and the affiliated professional contractors. The Compan y is a party to a joint venture in which it owns a 37.5 % economic interest. The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity. The Company was also a party to another joint venture in which it owned a 51 % economic interest and for which it was deemed the primary beneficiary. This joint venture was dissolved in February 2022. The operating results related to this joint venture prior to the dissolution and impacts from such dissolution were not material. The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K (the “Form 10-K”).

Data imported from MEDNAX Inc. SEC filings. Check original filings before making any investment decision.